Alpha-1 Antitrypsin (AAT) is used to treat hereditary AAT deficiency which leads to Congenital Emphysema.
David Tsur, CEO of Kamada, said: “The company’s intravenous Alpha-1 Antitrypsin (AAT) is the only ready-to-use AAT product that does not require reconstitution before use. Concurrently, Kamada is developing the next generation AAT for various indications, to be delivered by inhalation, directly to the lungs.”